



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

30th January, 2023

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai - 400 001

Scrip code: 531015

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 30th January, 2023
Ref: Pursuant to Reg.30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the subject cited above, we wish to inform you that the Board of Directors of the Company at its meeting held on Monday, the 30th January, 2023 at 4.00 P.M at registered office of the Company, inter alia,

- (i) Approved the un-audited Financial Results for the Quarter (Q3) and Nine Months ended December 31, 2022.


The meeting commenced at 4.00 p.m. and concluded at 4.30 p.m.


Request you to take the above information on records.

Thanking you,

Yours Faithfully,

For Venmax Drugs and Pharmaceuticals Limited


N. Krishnaiah
Director
DIN: 07279009



VENMAX DRUGS AND PHARMACEUTICALS LIMITED
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddi TG 500055
(CIN: L24230TG1988PLC009102)

Un-Audited Financial Results for the Quarter and Nine Months Ended 31st, December 2022

S No	Particulars	Quarter Ended			Nine Months ended		Year Ended
		Dec. 31st 2022	Sep. 30th 2022	Dec. 31st 2021	Dec. 31st 2022	Dec. 31st 2021	March 31st, 2022
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	a) Revenue from Operations	-	-	-	-	-	-
	Total Revenue from operations	-	-	-	-	-	-
	b) Other Income	5.00	5.00	-	15.00	-	198.30
	Total Income	5.00	5.00	0.00	15.00	-	198.30
2	Expenses						
	a) Cost of materials Consumed	-	-	-	-	-	-
	b) Changes in inventories	-	-	-	-	-	-
	c) Employee benefits expense	1.01	0.99	0.30	2.30	0.90	1.20
	d) Finance costs	-	-	-	-	-	-
	e) Depreciation and amortization expenses	0.20	0.20	0.23	0.60	0.68	0.91
	f) Other expenses	2.028	5.35	2.88	8.75	8.65	11.53
	Total Expenses (a to f)	3.24	6.54	3.41	11.65	10.23	13.65
3	Profit before tax (1-2)	1.76	(1.54)	(3.41)	3.35	(10.23)	184.66
4	Tax expenses						
	- Income Tax	-	-	-	-	-	-
	- Deferred Tax	(0.05)	(0.05)	0.01	0.06	0.02	0.03
5	Net Profit for the period (3-4)	1.81	(1.49)	(3.42)	3.29	(10.26)	184.62
6	Other comprehensive income						
	a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
7	Total Comprehensive income (5 +6)	1.81	(1.49)	(3.42)	3.29	(10.26)	184.62
8	Paid-up Equity Share Capital (Rs.10/- per Equity Share)	523.89	523.89	523.89	523.89	523.89	523.89
9	Other Equity						(617.90)
10	Earnings per share (Face Value of Rs.10/- each)						
	(a) Basic (In Rs.)	0.03	(0.03)	(0.07)	0.06	(0.20)	3.52
	(b) Diluted (In Rs.)	0.03	(0.03)	(0.07)	0.06	(0.20)	3.52

1 These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 (Indian Accounting Standards) Rules 2015 as amended by the companies (Indian Accounting standards) (amendment) rules 2016.

2 The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 30-01-2023.

3 The Financial results are revised by the statutory auditor's as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


4 The full format of the Quarterly Financial Results are available on company's website and the stock exchange's website www.bseindia.com.

5 Previous year/period figures have been regrouped, wherever necessary, inline with the current period/year presentation.

By and on behalf of the Board
For Venmax Drugs & Pharmaceuticals Limited

N. Krishnaiah
Nooka Krishnaiah
 Whole Time Director
 DIN: 07279009

Place : Hyderabad
 Date: 30-01-2023



VENMAX DRUGS AND PHARMACEUTICALS LIMITED
H.No.1-140, Rajeswari Ware House, Opposite to Sri Convention, Kompally, Quthbullapur Hyderabad Rangareddi TG 500055
(CIN: L24230TG1988PLC009102)
Extract of Un-audited financial results for the Quarter and Nine Months Ended 31st December, 2022

S. No	Particulars	Rs. In Lakhs											
		Quarter ended			Nine Months ended			Year ended					
		Dec. 31st 2022	Sep. 30th 2022	Dec. 31st 2021	Dec. 31st 2022	Dec. 31st 2021	Dec. 31st 2022	Dec. 31st 2021	Dec. 31st 2022	Dec. 31st 2021	Dec. 31st 2021	31.03.2022	
Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited		
1	Total income	5.00	5.00	0.00	15.00	0.00	15.00	0.00	15.00	0.00	198.30	198.30	
2	Net Profit (before Tax, Exceptional and/or Extraordinary items)	1.76	(1.54)	(3.41)	3.35	(3.41)	3.35	(10.23)	3.35	(10.23)	184.66	184.66	
3	Net Profit before tax (after Exceptional and/or Extraordinary items)	1.76	(1.54)	(3.41)	3.35	(3.41)	3.35	(10.23)	3.35	(10.23)	184.66	184.66	
4	Net Profit after tax (after Exceptional and/or Extraordinary items)	1.81	(1.49)	(3.42)	3.29	(3.42)	3.29	(10.26)	3.29	(10.26)	184.62	184.62	
5	Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	1.81	(1.49)	(3.42)	3.29	(3.42)	3.29	(10.26)	3.29	(10.26)	184.62	184.62	
6	Paid up Equity Share Capital (Rs.10/- Per Equity Share)	523.89	523.89	523.89	523.89	523.89	523.89	523.89	523.89	523.89	523.89	523.89	
7	Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year ended	-	-	-	-	-	-	-	-	-	(617.90)	(617.90)	
8	Earnings Per Share (of Rs. 10/- each) (Not Annualised):												
	a) Basic	0.03	(0.03)	(0.07)	0.06	(0.07)	0.06	(0.20)	0.06	(0.20)	3.52	3.52	
	b) Diluted	0.03	(0.03)	(0.07)	0.06	(0.07)	0.06	(0.20)	0.06	(0.20)	3.52	3.52	


The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 30-01-2023.
 Note : The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Un Audited Financial Results are available on company's website and the stock exchange's website www.bseindia.com.

Place : Hyderabad
 Date: 30-01-2023

By and on behalf of the Board
 For Venmax Drugs & Pharmaceuticals Limited



N. Prasad Rao
 Nooka Krishnaiah
 Whole Time Director
 DIN: 07279009



Limited Review Report on Unaudited Financial Results of
M/s Venmax Drugs and Pharmaceuticals Limited

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of **M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED** pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

To the board of directors of,
VENMAX DRUGS AND PHARMACEUTICALS LIMITED

We have reviewed the accompanying unaudited financial results of **M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED**, for the quarter ended 31st December 2022 and year to date results for the period from April 1st 2022 to 31st December 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with Standard on Review Engagements (**SRE**) **2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity'**, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement and nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position as at December 31, 2022.

For NSVR & Associates LLP
Chartered Accountants
FRN: 008801S/S200060


Suresh Ganhamani
Partner,
M No. 226870

UDIN: 23226870BGVRUY9518

Place: Hyderabad
Date: 30/01/2023.